151 related articles for article (PubMed ID: 9422389)
1. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo.
Gatley SJ; Lan R; Volkow ND; Pappas N; King P; Wong CT; Gifford AN; Pyatt B; Dewey SL; Makriyannis A
J Neurochem; 1998 Jan; 70(1):417-23. PubMed ID: 9422389
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand.
Lan R; Gatley J; Lu Q; Fan P; Fernando SR; Volkow ND; Pertwee R; Makriyannis A
AAPS PharmSci; 1999; 1(2):E4. PubMed ID: 11741201
[TBL] [Abstract][Full Text] [Related]
3. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.
Gatley SJ; Gifford AN; Volkow ND; Lan R; Makriyannis A
Eur J Pharmacol; 1996 Jul; 307(3):331-8. PubMed ID: 8836622
[TBL] [Abstract][Full Text] [Related]
4. [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients.
Berding G; Müller-Vahl K; Schneider U; Gielow P; Fitschen J; Stuhrmann M; Harke H; Buchert R; Donnerstag F; Hofmann M; Knoop BO; Brooks DJ; Emrich HM; Knapp WH
Biol Psychiatry; 2004 May; 55(9):904-15. PubMed ID: 15110734
[TBL] [Abstract][Full Text] [Related]
5. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281.
Cosenza M; Gifford AN; Gatley SJ; Pyatt B; Liu Q; Makriyannis A; Volkow ND
Synapse; 2000 Dec; 38(4):477-82. PubMed ID: 11044895
[TBL] [Abstract][Full Text] [Related]
6. Candidate PET radioligands for cannabinoid CB1 receptors: [18F]AM5144 and related pyrazole compounds.
Li Z; Gifford A; Liu Q; Thotapally R; Ding YS; Makriyannis A; Gatley SJ
Nucl Med Biol; 2005 May; 32(4):361-6. PubMed ID: 15878505
[TBL] [Abstract][Full Text] [Related]
7. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors.
Gatley SJ; Lan R; Pyatt B; Gifford AN; Volkow ND; Makriyannis A
Life Sci; 1997; 61(14):PL 191-7. PubMed ID: 9335234
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
9. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
Meschler JP; Kraichely DM; Wilken GH; Howlett AC
Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
[TBL] [Abstract][Full Text] [Related]
10. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
[TBL] [Abstract][Full Text] [Related]
11. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH
Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794
[TBL] [Abstract][Full Text] [Related]
12. In vitro metabolism of diarylpyrazoles, a novel group of cannabinoid receptor ligands.
Zhang Q; Ma P; Wang W; Cole RB; Wang G
Drug Metab Dispos; 2005 Apr; 33(4):508-17. PubMed ID: 15616153
[TBL] [Abstract][Full Text] [Related]
13. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
Petitet F; Jeantaud B; Capet M; Doble A
Biochem Pharmacol; 1997 Dec; 54(11):1267-70. PubMed ID: 9416978
[TBL] [Abstract][Full Text] [Related]
14. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors.
Breivogel CS; Scates SM; Beletskaya IO; Lowery OB; Aceto MD; Martin BR
Eur J Pharmacol; 2003 Jan; 459(2-3):139-50. PubMed ID: 12524139
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
Lan R; Liu Q; Fan P; Lin S; Fernando SR; McCallion D; Pertwee R; Makriyannis A
J Med Chem; 1999 Feb; 42(4):769-76. PubMed ID: 10052983
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Showalter VM; Compton DR; Martin BR; Abood ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
